According to Dun & Bradstreet, the principal for Evita Solutions—a pharmaceutical manufacturer—is Robert Patane, and the business is located in Glen Allen, Virginia. According to Susan B. Anthony Pro-Life America, Evita Solutions describes its mission as one to "normalize abortion" and make it "accessible to all."

Key Takeaways:

• On Tuesday, the FDA quietly approved a new generic version of the abortion drug mifepristone.

• The company behind the generic mifepristone is Evita Solutions LLC, which said its mission is to "normalize abortion" and make it "accessible to all."

• The decision comes just days after HHS Secretary Robert F. Kennedy Jr said that the FDA will be reviewing the safety of mifepristone.

• Kennedy had previously accused the Biden administration of having "twisted the data" on the safety of the abortion pill.

The Details:

On Tuesday, the FDA quietly approved a new generic version of the abortion pill Mifeprex, as stated in a letter sent to Evita Solutions, LLC. Evita Solutions had previously sent an abbreviated new drug application (ANDA) for mifepristone to the FDA on October 1, 2021.

In the letter, the FDA said the generic mifepristone tablets, 200 mg, are approved for use as of the date of the letter: September 30, 2025.

"We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act," states the letter. "Accordingly the ANDA is approved, effective on the date of this letter. We have determined your Mifepristone Tablets, 200 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mifeprex (mifepristone) tablets, 200 mg, of Danco Laboratories, LLC NDA - 020687."

The letter also states that the FDA will determine if a risk evaluation and mitigation strategy (REMS) "is necessary to ensure that the benefits of the drug outweigh the risks":

"The details of the REMS requirements were outlined in our REMS notification letter dated January 26, 2022.

The Mifepristone REMS Program is an approved single, shared system (SSS) REMS for mifepristone 200 mg tablets, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation; it includes Elements to Assure Safe Use (ETASU) and an implementation system.

Your final proposed REMS, received on April 16, 2025 is approved. Your product will be included in the Mifepristone REMS Program and will be posted on the FDA REMS website: http://www.fda.gov/rems."

The REMS must be "fully operational" before the drug is made available for purchase.

The news of the FDA's approval of a generic version of Mifeprex comes just days after HHS Secretary Robert F. Kennedy Jr. said the FDA is reviewing the safety of Mifeprex itself. In June, Kennedy asked FDA Commissioner Martin Makary to "review the latest data" on the drug. He has accused the Biden administration of having "twisted the data" on the safety of the abortion pill.

In a letter dated September 19, Kennedy and Makary wrote, "HHS— through the FDA—is conducting its own review of the evidence, including real-world outcomes and evidence, relating to the safety and efficacy of the drug [mifepristone]."

Kennedy and Makary did not say when the review would be completed, but said, "We will keep you informed as the FDA's review of mifepristone progresses."

What We're Hearing:

Reaction to this decision from pro-life politicians and others has been swift:

Senator Josh Hawley wrote on X, "This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child."

In a follow-up tweet, he wrote, "FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they've just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA."

Live Action founder and president Lila Rose responded to Hawley's original tweet, calling on Secretary Kennedy to reverse the decision:

UNACCEPTABLE: The FDA just approved another generic of the abortion pill mifepristone. This drug starves babies and harms mothers! The FDA just said it would do a new serious safety study—so why approve a another generic now? @RobertKennedyJr must reverse this decision! @LilaGraceRose

Former VP Mike Pence also took to X to share his thoughts, writing, "The Trump Administration's approval of a generic chemical abortion drug is a complete betrayal of the pro-life movement that elected President Trump... President Trump must immediately reverse this decision. RFK must resign and give President Trump the opportunity to appoint a new Secretary of HHS who will protect the sanctity of life. The fight for life continues."

The Trump Administration's approval of a generic chemical abortion drug is a complete betrayal of the pro-life movement that elected President Trump.

The Backstory:

Mifepristone was first approved for use up to seven weeks of pregnancy in the United States under the Clinton administration in 2020. In 2011, the FDA placed mifepristone under its REMS safety system, but not before multiple women had died in association with the use of the abortion pill regimen, which includes a second drug, misoprostol. Under the Obama administration and the Biden administration, the REMS was significantly weakened, and ultimately, the abortion pill began to be distributed via the mail. Read the full timeline here.

The abortion pill was sold to women as safe, but its supposed safety was based on years of lies. As reported by Live Action research fellow Carole Novielli, the abortion industry has been encouraging women to lie to ER staff about taking the abortion pill when they experience emergency complications. This repeated lie has skewed the data, making the abortion pill appear safe and pregnancy look dangerous.

An analysis published by the Ethics and Public Policy Center of insurance data revealed that the abortion pill's serious adverse events rate is 22 times higher than the FDA's currently listed adverse events rate for mifepristone. According to that study, nearly 11% of women who take mifepristone suffer a severe complication, and a study out of Ireland found nearly the same result, with 12% of women going to the emergency room for complications.

Novielli explained, "Abortion pill prescribers offload their patients to ERs, encouraging women to lie if injured→neither prescribers nor ER personnel learn the truth about the adverse events→no one reports those adverse events to the manufacturer→the manufacturer never learns of the adverse events to report to FDA→the FDA stays in the dark about true complications, impacting safeguards." Subscribe for free to Breaking Christian News here

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Leftists Try to Shut Down Pro-Charlie Kirk Coffee Shop: 'But God is Good'

Dr. Jordan Peterson Was 'Near Death' Over the Summer

'Playing God': Shocking Research Turns Skin Cells into Human Eggs [Video]

'Unacceptable': Despite Promising a Safety Review, FDA Approves Another Generic Abortion Pill

Mainstream Media Goes All in on Woke Pronouns over Chief Justice Kavanaugh's Would-Be Assassin

Rank-And-File DC Officers Accuse Superiors of Downgrading Crimes to Mask Real Levels: Report

Trump's Deployment of National Guard Troops to Handle Antifa in Portland Halted by Federal Judge

Israeli Delegation Heads to Egypt for Hostage Talks with Hamas

Good News: TPUSA High School Clubs More Than Double, Hit 2,700 Nationwide

Atheist Bill Maher Condemns Media Silence on Christian Genocide in Nigeria: 'Systematic Killing'

'We Found Him': The Alleged Smoke Bomber Who Disrupted a Sean Feucht Worship Event; His Shocking Links to Antifa Inside Canada's Military

As Deadly Violence against Houses of Worship Rises, So Do Law Enforcement, Security Measures

Portland Police Arrest Conservative Journalist Nick Sortor Outside ICE Facility, 'But None of the Domestic Terrorists'

Apple Takes Down ICE Tracking Apps After Pressure from Bondi DOJ

Kash Patel's FBI Cuts All Ties to Southern Poverty Law Center

The President Is Already Using the Shutdown to Slash Federal Spending, Plans to Make Job Cuts

Israeli Leaders React to Terror Attack on UK Synagogue as Navy Intercepts Pro-Hamas Flotilla

President Trump Sets Sunday Deadline for Hamas to Accept Deal or Face 'ALL HELL'

Hamas Says It Will Release All Remaining Hostages, But...

'Blown Away': Hundreds Saved and Baptized as 8,000 Students Seek Jesus at University of Tennessee